Target Name: MYMX
NCBI ID: G101929726
Other Name(s): CFZS2 | MINION | Myomerger | myomixer, myoblast fusion factor | Protein myomixer | Protein minion | uncharacterized LOC101929726 | myomerger | protein minion | MYMX variant 1 | hMINION | Microprotein inducer of fusion | microprotein inducer of fusion | Myomixer, myoblast fusion factor, transcript variant 1 | MYMX_HUMAN

CFZS2: A Potential Drug Target for Myeloid-Derived Suppressor Protein (MYMX)

Myeloid-derived suppressor protein (MYMX) is a protein that is expressed in the myeloid cells of the human body. It is a key regulator of the immune response and has been implicated in the development of many diseases, including leukemia, infections, and autoimmune disorders. In recent years, researchers have been interested in developing drugs that target MYMX as a potential therapeutic approach for these diseases.

One of the proteins that has been identified as a potential drug target for MYMX is CFZS2. CFZS2 is a protein that is expressed in the erythrocytes (red blood cells) and is known for its role in the development and maintenance of the erythrocyte membrane. It is composed of two transmembrane domains, a cytoplasmic tail, and an extracellular domain that is involved in cell signaling and adhesion.

CFZS2 has been shown to be involved in many different processes that are important for the development and maintenance of the erythrocyte membrane. For example, it has been shown to play a role in the regulation of cell adhesion, cell signaling, and the production of reactive oxygen species (ROS). It is also involved in the formation of the erythrocyte membrane and in the maintenance of the integrity of the membrane.

One of the ways that researchers have investigated the potential drug target of CFZS2 is through the use of cell-based assays. These assays involve the use of live cells that have been genetically modified to express CFZS2. Researchers have used these cells to study the effects of drugs on the behavior of the cells and have found that some drugs have the potential to inhibit the activity of CFZS2.

Another way that researchers have investigated the potential drug target of CFZS2 is through the use of animal models. They have used mice or other animals to study the effects of drugs on the behavior of the animals and have found that some drugs have the potential to inhibit the activity of CFZS2 in these animals.

In addition to its potential as a drug target, CFZS2 has also been identified as a potential biomarker for the development of certain diseases. For example, some studies have suggested that high levels of CFZS2 may be associated with an increased risk of developing certain types of cancer. Additionally, some researchers have suggested that CFZS2 may be involved in the development of autoimmune disorders.

Overall, CFZS2 is a protein that has been identified as a potential drug target for the development of many different diseases. Further research is needed to fully understand its role and to develop effective treatments for the disorders that are associated with its activity.

Protein Name: Myomixer, Myoblast Fusion Factor

Functions: Myoblast-specific protein that mediates myoblast fusion, an essential step for the formation of multi-nucleated muscle fibers (PubMed:28569745, PubMed:35642635). Involved in membrane fusion downstream of the lipid mixing step mediated by MYMK (By similarity). Acts by generating membrane stresses via its extracellular C-terminus, leading to drive fusion pore formation. Acts independently of MYMK (By similarity). Involved in skeletal muscle regeneration in response to injury by mediating the fusion of satellite cells, a population of muscle stem cells, with injured myofibers (By similarity)

More Common Targets

MYNN | MYO10 | MYO15A | MYO15B | MYO16 | MYO16-AS1 | MYO16-AS2 | MYO18A | MYO18B | MYO19 | MYO1A | MYO1B | MYO1C | MYO1D | MYO1E | MYO1F | MYO1G | MYO1H | MYO3A | MYO3B | MYO3B-AS1 | MYO5A | MYO5B | MYO5C | MYO6 | MYO7A | MYO7B | MYO9A | MYO9B | MYOC | MYOCD | MYOD1 | MYOF | MYOG | MYOM1 | MYOM2 | MYOM3 | MYORG | Myosin | Myosin class II | Myosin light-chain phosphatase | MYOSLID | MYOSLID-AS1 | MYOT | MYOZ1 | MYOZ2 | MYOZ3 | MYPN | MYPOP | MYRF | MYRF-AS1 | MYRFL | MYRIP | MYSM1 | MYT1 | MYT1L | MYT1L-AS1 | MYZAP | MZB1 | MZF1 | MZF1-AS1 | MZT1 | MZT2A | MZT2B | N-acetylglucosamine-1-phosphotransferase | N-CoR deacetylase complex | N-Terminal Acetyltransferase A (NatA) Complex | N-Terminal Acetyltransferase C (NatC) Complex | N-Type Calcium Channel | N4BP1 | N4BP2 | N4BP2L1 | N4BP2L2 | N4BP2L2-IT2 | N4BP3 | N6AMT1 | NAA10 | NAA11 | NAA15 | NAA16 | NAA20 | NAA25 | NAA30 | NAA35 | NAA38 | NAA40 | NAA50 | NAA60 | NAA80 | NAAA | NAALAD2 | NAALADL1 | NAALADL2 | NAALADL2-AS3 | NAB1 | NAB2 | NABP1 | NABP2 | NACA | NACA2